Ghent University Academic Bibliography

Advanced

Secukinumab : IL-17A inhibition to treat psoriatic arthritis

Reinhart Speeckaert, Nanja van Geel UGent, Jo Lambert UGent, L Claeys, Joris Delanghe UGent and Marijn Speeckaert UGent (2017) DRUGS OF TODAY. 52(11). p.607-616
abstract
Interleukin-17A is an important cytokine in the pathogenesis of psoriatic arthritis. Secukinumab is a recombinant, high-affinity, fully human immunoglobulin G1 kappa monoclonal antibody with a selective binding and neutralization of interleukin-17A. By providing an alternative mechanism of action to current treatments, secukinumab has shown efficacy in the key clinical domains of psoriatic arthritis. In the present paper, we discuss the role of interleukin-17A as a clinically relevant target in the treatment of psoriatic arthritis, based on preclinical findings, dose-ranging and regimen-finding, randomized, placebo-controlled clinical trials.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
bDMARDs, IL-17A, Psoriatic arthritis, Secukinumab, Monoclonal antibodies, Psoriasis, COLLAGEN-INDUCED ARTHRITIS, ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY, RANDOMIZED CONTROLLED-TRIAL, NECROSIS-FACTOR-ALPHA, DOUBLE-BLIND, CARTILAGE DESTRUCTION, JOINT INFLAMMATION, PLAQUE PSORIASIS, BONE EROSION, EULAR RECOMMENDATIONS
journal title
DRUGS OF TODAY
Drugs Today
volume
52
issue
11
pages
607 - 616
Web of Science type
Article
Web of Science id
000392728600002
ISSN
1699-3993
DOI
10.1358/dot.2016.52.11.2526754
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
8525102
handle
http://hdl.handle.net/1854/LU-8525102
date created
2017-06-26 11:38:17
date last changed
2017-09-25 13:05:45
@article{8525102,
  abstract     = {Interleukin-17A is an important cytokine in the pathogenesis of psoriatic arthritis. Secukinumab is a recombinant, high-affinity, fully human immunoglobulin G1 kappa monoclonal antibody with a selective binding and neutralization of interleukin-17A. By providing an alternative mechanism of action to current treatments, secukinumab has shown efficacy in the key clinical domains of psoriatic arthritis. In the present paper, we discuss the role of interleukin-17A as a clinically relevant target in the treatment of psoriatic arthritis, based on preclinical findings, dose-ranging and regimen-finding, randomized, placebo-controlled clinical trials.},
  author       = {Speeckaert, Reinhart and van Geel, Nanja and Lambert, Jo and Claeys, L and Delanghe, Joris and Speeckaert, Marijn},
  issn         = {1699-3993},
  journal      = {DRUGS OF TODAY},
  keyword      = {bDMARDs,IL-17A,Psoriatic arthritis,Secukinumab,Monoclonal antibodies,Psoriasis,COLLAGEN-INDUCED ARTHRITIS,ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY,RANDOMIZED CONTROLLED-TRIAL,NECROSIS-FACTOR-ALPHA,DOUBLE-BLIND,CARTILAGE DESTRUCTION,JOINT INFLAMMATION,PLAQUE PSORIASIS,BONE EROSION,EULAR RECOMMENDATIONS},
  language     = {eng},
  number       = {11},
  pages        = {607--616},
  title        = {Secukinumab : IL-17A inhibition to treat psoriatic arthritis},
  url          = {http://dx.doi.org/10.1358/dot.2016.52.11.2526754},
  volume       = {52},
  year         = {2017},
}

Chicago
Speeckaert, Reinhart, Nanja van Geel, Jo Lambert, L Claeys, Joris Delanghe, and Marijn Speeckaert. 2017. “Secukinumab : IL-17A Inhibition to Treat Psoriatic Arthritis.” Drugs of Today 52 (11): 607–616.
APA
Speeckaert, R., van Geel, N., Lambert, J., Claeys, L., Delanghe, J., & Speeckaert, M. (2017). Secukinumab : IL-17A inhibition to treat psoriatic arthritis. DRUGS OF TODAY, 52(11), 607–616.
Vancouver
1.
Speeckaert R, van Geel N, Lambert J, Claeys L, Delanghe J, Speeckaert M. Secukinumab : IL-17A inhibition to treat psoriatic arthritis. DRUGS OF TODAY. 2017;52(11):607–16.
MLA
Speeckaert, Reinhart, Nanja van Geel, Jo Lambert, et al. “Secukinumab : IL-17A Inhibition to Treat Psoriatic Arthritis.” DRUGS OF TODAY 52.11 (2017): 607–616. Print.